CytoDyn Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Accounts Payable and Accrued Liabilities

Accounts Payable and Accrued Liabilities

12 Months Ended

May 31, 2023

Accounts Payable and Accrued Liabilities

Accounts Payable and Accrued Liabilities

Note 5. Accounts Payable and Accrued Liabilities

As of May 31, 2023 and 2022, the accounts payable balance was approximately $62.7 million and $68.0 million, respectively. The Company had two vendors that together accounted for approximately 72% and 73% of the total balance of accounts payable as of each respective date.

The components of accrued liabilities were as follows:


(in thousands)		May 31, 2023		May 31, 2022
Compensation and related expense	$	335	$	1,522
Legal fees and settlement		168		2,006
Clinical expense		187		3,727
Accrued inventory charges and expenses		4,978		1,392
License fees		862		150
Lease payable		139		134
Other liabilities		—		64
Total accrued liabilities	$	6,669	$	8,995

As of May 31, 2023 and 2022, the accrued legal fees and settlement balance was primarily related to legal fees.